Yehoda M Martei, MD, MSCE

faculty photo
Assistant Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania
Department: Medicine

Contact information
3400 Civic Center Blvd.
Philadelphia, PA 19104
BA (Biology)
Harvard University, 2005.
MD (Medicine)
Yale University School of Medicine, 2011.
MSCE (Clinical Epidemiology)
University of Pennsylvania, 2018.
Permanent link
> Perelman School of Medicine   > Faculty   > Details

Selected Publications

Martei YM, Obasohan M, Mokokwe L, Ralefala T, Mosepele M, Gross R, Barg FK.: Stigma and Social Determinants of Health Associated With Fidelity to Guideline-Concordant Therapy in Patients With Breast Cancer Living With and Without HIV in Botswana. Oncologist 28: e1230-e1238, Dec 2023.

O'Neil DS, Martei YM, Crew KD, Castillo BS, Costa P, Lim T, Michel A, Rubin E, Goel N, Hurley J, Lopes G, Antoni MH.: Time to Cancer Treatment and Chemotherapy Relative Dose Intensity for Patients With Breast Cancer Living With HIV. JAMA Netw Open 6: e2346223, Dec 2023.

Kizub DA, Naik S, Abogan AA, Pain D, Sammut S, Shulman LN, Martei YM.: Access to and Affordability of World Health Organization Essential Medicines for Cancer in Sub-Saharan Africa: Examples from Kenya, Rwanda, and Uganda. Oncologist 27(11): 958-970, Nov 2023 Notes: DOI: 10.1093/oncolo/oyac143

Chasimpha S, Dos Santos Silva I, Martei YM, Grover S, Cubasch H, McCormack V.: Survival Disparities Between Patients with Breast Cancer With and Without HIV: A Research Framework. JCO Glob Oncol 2023.

Motlokwa PK, Tsima BM, Martei YM, Ralefala T, Galebole F, Stephens-Shields AJ, Grover S, Gross R.: Disparities in Oral Cancer Stage at Presentation in a High HIV Prevalence Setting In Sub-Saharan Africa. JCO Glob Oncol 8: e2100439, Aug 2022 Notes: DOI: 10.1200/GO.21.00439

Martei YM, Narasimhamurthy M, Setlhako DI, Ayane G, Ralefala T, Chiyapo S, Gross R, Shulman LN, Grover S, DeMichele A.: Relative Dose Intensity and Pathologic Response Rates in Patients With Breast Cancer and With and Without HIV Who Received Neoadjuvant Chemotherapy. JCO Glob Oncol 8: e2200016. May 2022 Notes: DOI: 10.1200/GO.22.00016

Martei YM, Grover S, Narasimhamurthy M, Setlhako DI, Ayane GN, Ralefala TB, Chiyapo SP, Gross R, DeMichele A, Shulman LN : Relative dose intensity and pathologic response rates in HIV-infected and HIV-uninfected breast cancer patients who received neoadjuvant chemotherapy. Journal of Clinical Oncology 18(15 Suppl e19140): e2200016, May 2022.

Martei YM, Clark AS.: Navigating Systemic Therapeutic Options for First-Line Metastatic Hormone Receptor-Positive, ERBB2-Negative Breast Cancer Treatment. JAMA Netw Open 5: e224380, Apr 2022.

Martei YM, Dauda B, Vanderpuye V.: Correction: Breast cancer screening in sub-Saharan Africa: a systematic review and ethical appraisal. BMC Cancer 22(1): 306, Mar 2022.

Razis E, Kassapian M, Andriakopoulou C, Martei YM, Zurn SJ, Hammad N, Romero Y, Dafni U, Ilbawi AM, Trapani D.: Essential medicines list in national cancer control plans: a secondary analysis from a global study. Lancet Oncol 23(3): e144-154, Mar 2022.

back to top
Last updated: 12/17/2023
The Trustees of the University of Pennsylvania